Sunbird Bio, a biotech company, is developing protein-based diagnostic tests that empower diagnosis and treatment of Alzheimer's disease, neurological disorders, and early-stage cancer.
Sunbird Bio operates as a biotechnology company. It focuses on developing protein-based diagnostic tests. The company's main offerings include diagnostic tests to provide insights for the diagnosis and treatment of Alzheimer’s disease, other neurological disorders, and early-stage cancer. Sunbird Bio...
新加坡,2024年10月17日 —— 新加坡诊断平台开发商Sunbird Bio近日完成A轮融资,投资方包括ClavystBio, EDB Investments, Lilly Ventures, Polaris Partners和S32。 Sunbird Bio是一家成立于2021年的诊断平台开发商,专注于通过分子诊断提供快速和准确的结果。该公司的平台专门检测各种疾病,包括传染病、神经退行性疾病和癌...
Sunbird Bio获得1400万美元A轮融资 近日,Sunbird Bio宣布已经在一轮融资中筹集了1400万美元(约折合人民币9971万元)。此次融资由新投资者礼来公司、新加坡经济发展局战略投资部门以及现有投资者ClavystBio、Polaris Partners和S32提供。 Sunbird Bio是一家诊断平台开发商,旨在通过分子诊断提供快速和准确的结果,该公司的平台...
新加坡,2024年10月17日 —— 新加坡诊断平台开发商Sunbird Bio近日完成A轮融资,投资方包括ClavystBio, EDB Investments, Lilly Ventures, Polaris Partners和S32。 Sunbird Bio是一家成立于2021年的诊断平台开发商,专注于通过分子诊断提供快速和准确的结果。该公司的平台专门检测各种疾病,包括传染病、神经退行性疾病和癌...
Sunbird Bio has raised $14M over 2 rounds. Sunbird Bio's latest funding round was a Seed VC for $14M on October 16, 2024. Date Round Amount Investors Valuation Revenue Sources 10/16/2024 Seed VC $14M ClavystBio, EDBI, Eli Lilly and Company, Polaris Growth Fund, and Section 32 $XX...
Sunbird Bio, a biotechnology company developing proprietary protein-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced that they have completed a merger with Glympse Bio to accelerate development of th...
Our dedication and passion is evident through our team of trained professional cleaners who make use of best products and techniques to clean carpets. We believe in conservation of nature and take this responsibility seriously by using only bio-degradable products for carpet cleaning processes....
新加坡,2024年10月17日 —— 新加坡诊断平台开发商Sunbird Bio近日完成A轮融资,投资方包括ClavystBio, EDB Investments, Lilly Ventures, Polaris Partners和S32。 Sunbird Bio是一家成立于2021年的诊断平台开发商,专注于通过分子诊断提供快速和准确的结果。该公司的平台专门检测各种疾病,包括传染病、神经退行性疾病和癌...
近日,Sunbird Bio宣布已经在一轮融资中筹集了1400万美元(约折合人民币9971万元)。此次融资由新投资者礼来公司、新加坡经济发展局战略投资部门以及现有投资者ClavystBio、Polaris Partners和S32提供。